ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξγεεηϊ ςμ δϊεφΰεϊ μψαςεο δωμιωι ωμ 200607/11/2006
δξλιψεϊ αψαςεο ςμε α- 74% εδρϊλξε α- 2,286 ξμιεο $
δψεεη πχι ςμδ α- 127% εδρϊλν α- 606 ξμιεο $
ψεεη μξπιδ αγιμεμ ξμΰ ςμδ α- 85% μ- 0.74$
ϊζψιν ξζεξπιν ξτςιμεϊ ωεθτϊ δρϊλν α- 793 ξμιεο $
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ γιεεηδ διεν ςμ ϊεφΰεϊ δψαςεο δωμιωι ωδρϊιιν α- 30 αρτθξαψ, 2006.
δξλιψεϊ αψαςεο δωμιωι ωμ 2006 ςμε α- 74% εδρϊλξε α- 2,286 ξμιεο $, αδωεεΰδ μ- 1,317 ξμιεο $ αψαςεο δξχαιμ ΰωϊχγ. δϊψεξδ δςιχψιϊ μφξιηδ αξλιψεϊ αδωεεΰδ μΰωϊχγ διϊδ δωχεϊ ωμ ξρτψ ξεφψιν ηγωιν αΰψδ"α εδλμμϊ ξλιψεϊ IVAX, ΰωψ ϊψξε μλμ δΰιζεψιν.
δψεεη δπχι μψαςεο δωμιωι ωμ 2006 ςμδ α- 127% εδρϊλν α- 606 ξμιεο $ μςεξϊ 267 ξμιεο $ αψαςεο δξχαιμ ΰωϊχγ. ψεεη μξπιδ αγιμεμ ξμΰ, δρϊλν α- 0.74$, βιγεμ ωμ 85% αδωεεΰδ μ- 0.40$ αψαςεο δωμιωι ωμ 2005.
ιωψΰμ ξχεα, πωιΰ εξπλ"μ θας ΰξψ: "διδ ζδ ατιψεω ψαςεο ξςεμδ ςαεψ θας, ψαςεο ωιΰ αϊεφΰεϊ δτιππριεϊ ωμ θας ΰωψ παςε ξαιφεςιν ηζχιν ωμ λμ διηιγεϊ δςρχιεϊ εδϊτςεμιεϊ ωμπε, αλμ δΰιζεψιν δβιΰεβψτιιν εαλμμν ϊεφΰεϊ ωιΰ αφτεο ΰξψιχδ εαηθιαδ δαιπμΰεξιϊ. δδωβιν δαεμθιν αψαςεο ζδ διε, λξεαο, δδωχεϊ δξεφμηεϊ αξιεηγ ωμ ωπι ξεφψιν βπψιιν βγεμιν αΰψδ"α εδδωχδ δξφειιπϊ αωεχ δΰξψιχΰι ωμ ΰζιμχθ®, δξεφψ διηεγι δωπι ωμ θας. ΰπι ξΰξιο λι διωβιν ΰμε ξελιηιν ΰϊ δξωξςεϊ εδςψκ δΰξιϊιιν ωμ διεϊπε ξπδιβι δϊςωιιδ."
ξψ ξχεα δερισ: "λξε λο ΰπι ξψεφδ ξΰεγ ξδδϊχγξεϊ δξδιψδ εδξφειιπϊ ωμ ϊδμικ δΰιπθβψφιδ ςν IVAX. ΰπε λαψ ξξξωιν ριπψβιεϊ ςφεξεϊ ξψλιωδ ζε εΰπε ξξεφαιν διθα μξξω ΰϊ λμ δδζγξπειεϊ δθξεπεϊ αψλιωδ ζε."
δξλιψεϊ αφτεο ΰξψιχδ διεε 62% ξλμμ ξλιψεϊ δηαψδ, λΰωψ ΰιψετδ διεεϊδ 23%, εξλιψεϊ αιπμΰεξιεϊ (αςιχψ ΰξψιχδ δμθιπιϊ, ξψλζ εξζψη ΰιψετδ ειωψΰμ) διεε 15%.
δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ (λεμμ χετχρεο®) δρϊλξε α- 1.325 ξμιΰψγ $ αψαςεο, αδωεεΰδ μ- 707 ξμιεο $ αψαςεο δωμιωι ωμ 2005, βιγεμ ωμ 87%. δξλιψεϊ δεωτςε μθεαδ αψαςεο δωμιωι ξδλμμϊν ωμ 22 ξεφψιν ηγωιν ωμΰ πξλψε αψαςεο δξχαιμ ΰωϊχγ, λωδςιχψιιν αιπιδν αϊχετδ ζε δο δδωχεϊ αξρβψϊ αμςγιεϊ ωμ simvastatin, venlafaxine ,sertraline ε- pravastatin, βιγεμ αξλιψεϊ δχετχρεο® λξε βν ξξλιψεϊ δϊημϊιεϊ ωμ ΰζιμχθ® αΰψδ"α.
πλεο μ- 6 απεαξαψ, 2006, μθας 144 αχωεϊ δξξϊιπεϊ μΰιωεψ ρετι ωμ ψωεϊ δξζεο εδϊψετεϊ δΰξψιχΰιϊ (FDA). ρκ δξλιψεϊ δωπϊιεϊ ωμ αχωεϊ ΰμδ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, διπε λ- 87 ξμιΰψγ $. θας ξΰξιπδ λι διπδ δψΰωεπδ μδβιω αχωδ μΰιωεψ ςαεψ 44 ξεφψιν ξϊεκ αχωεϊ ΰμδ, δξωχτιν αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, ξςμ μ- 34 ξμιΰψγ $.
δξλιψεϊ δτψξφαθιεϊ αΰιψετδ (λεμμ χετχρεο®) βγμε α- 36% αψαςεο εδρϊλξε α- 464 ξμιεο $. απερσ μψλιωδ ωμ IVAX, δβιγεμ πεας ξξλιψεϊ βπψιεϊ βαεδεϊ ιεϊψ (δλεμμεϊ ΰϊ δωχϊν ωμ 34 ξεφψιν α- 9 ωεεχιν αψαςεο ζδ) εξβιγεμ αξλιψεϊ δχετχρεο®.
ξλιψεϊ τψξφαθιεϊ αιπμΰεξιεϊ, δλεμμεϊ αςιχψ ΰϊ ΰξψιχδ δμθιπιϊ, ξγιπεϊ ξψλζ εξζψη ΰιψετδ ειωψΰμ, βγμε δψαςεο α- 149% εδρϊλξε α- 309 ξμιεο $. δβιγεμ πεας ξδερτδ ωμ ωεεχιν ηγωιν, αΰξψιχδ δμθιπιϊ εξψλζ εξζψη ΰιψετδ, λϊεφΰδ ξψλιωϊ IVAX, λξε βν δψηαϊ δξλιψεϊ αωεεχιν χιιξιν.
χετχρεο® - δξλιψεϊ δβμεαμιεϊ ωμ χετχρεο®, αξεπηι ξηιψ ξλιψδ μωεχ, δρϊλξε αψαςεο ζδ α- 354 ξμιεο $, βιγεμ ωμ 15% αδωεεΰδ μψαςεο δξχαιμ α- 2005. ξλιψεϊ δχετχρεο® αΰψδ"α, αξεπηι ξλιψδ μωεχ, βγμε α- 10% εδρϊλξε α- 226 ξιμιεο $. ξλιψεϊ δχετχρεο®, αξεπηι ξλιψδ μωεχ, ξηευ μΰψδ"α, αςιχψ αΰιψετδ εαχπγδ, βγμε α- 26% μ-128 ξιμιεο $. μτι πϊεπι δ-IMS αΰψδ"α, χετχρεο® ξξωικ μφξεηξδψ ιεϊψ ξφξιηϊ δωεχ εμηζχ ΰϊ ξςξγε λξεαιμ ςν ςμιιδ απϊη ωεχ ξρκ λμ δξψωξιν αΰψδ"α (TRx) ερκ λμ δξψωξιν δηγωιν αΰψδ"α (NRx) μ- 34% ε- 35.2% ,αδϊΰξδ, πλεο μηεγω ρτθξαψ 2006.
ΰζιμχθ® - δξεϊεεδ μθιτεμ αϊρξιπιν ωμ ξημϊ τψχιπρεο λθιτεμ ιηιγπι δϊημϊι ΰε λθιτεμ ξωεμα ςν levodopa, δεωχ αηεγω ιεμι δΰηψεο αΰψδ"α εξεϊψ μωιξεω λςϊ α- 22 ξγιπεϊ.
ξλιψεϊ δλιξιδ (API) λεμμ ξλιψεϊ τπιξιεϊ μςρχιδ δτψξφαθιιν ωμ θας, δρϊλξε α- 321 ξμιεο $, βιγεμ ωμ 22% μςεξϊ δψαςεο δωμιωι α- 2005. ξλιψεϊ δ- API μφγγιν ωμιωιιν δρϊλξε α- 141 ξμιεο $, βιγεμ ωμ 3% μςεξϊ δψαςεο δξχαιμ ΰωϊχγ. ςιχψ δβιγεμ αξλιψεϊ τπιξιεϊ ξωχσ δψηαδ ωμ δΰιπθβψφιδ δΰπλιϊ ωμ θας.
ωιςεψ δψεεη δβεμξι δβις μ- 55.2% αψαςεο δωμιωι ωμ 2006 αδωεεΰδ μωιςεψ ψεεη βεμξι ωμ 47.0% αψαςεο δωμιωι ωμ 2005 εωμ 47.2% αωπϊ 2005 λεμδ. ωιςεψ ξϊξωκ ζδ ωμ ψεεη βεμξι βαεδ αΰετο ιεφΰ γετο, ξωχσ ΰϊ δξηζεψ δβαεδ ωμ ξλιψεϊ ξεφψιν ηγωιν αΰψδ"α, δπδπιν ξαμςγιεϊ εΰωψ μημχν ΰιπθβψφιδ ΰπλιϊ, λξε βν ωιςεψι ψεεη βαεδιν ιεϊψ ωμ δξεφψιν διηεγιν εξεφψι δξεϊβ ωμ θας.
δεφΰεϊ ξηχψ ετιϊεη (ξε"τ) πθε βγμε α- 45% αδωεεΰδ μψαςεο δξχαιμ ΰωϊχγ εδρϊλξε α - 134 ξμιεο $.
δεφΰεϊ ξλιψδ, δπδμδ ελμμιεϊ (SG&A) διεε 17.7% ξδξλιψεϊ εδρϊλξε α- 404 ξμιεο $ αδωεεΰδ μ- 16.2% ξρκ δξλιψεϊ ε- 214 ξμιεο $ αψαςεο δωμιωι ωμ 2005. ψξεϊ βαεδεϊ ΰμδ ξωχτεϊ αςιχψ ΰϊ διηρ δβαεδ ξωξςεϊιϊ ,αϊξδιμ δξεφψιν δπεληι ωμ θας, ωμ ϊψετεϊ ξχεψ εϊψετεϊ βπψιεϊ ξξεϊβεϊ, ΰωψ ψαεϊ ξδο περτε λϊεφΰδ ξψλιωϊ IVAX εΰωψ ξΰετιπεϊ αψξεϊ βαεδεϊ ιεϊψ ωμ δεφΰεϊ SG&A. δεφΰεϊ SG&A αψαςεο ζδ λμμε βν ψιωεν ωμ δεφΰεϊ αβιο ΰετφιεϊ μςεαγιν ωδρϊλξε αλ- 1 ρπθ μξπιδ.
ωιςεψ δξρ ωπχας αψαςεο ζδ δεΰ 12.5% ξδδλπρδ μτπι ξρ. ωιςεψ ζδ ξϊχο ΰϊ ωιςεψ δξρ δωπϊι ξ- 17.5% μ-15.5% ξδψεεη δωπϊι δξεϊΰν, δξωχσ ΰϊ δςψλϊπε δπεληιϊ μβαι ωπϊ 2006 λεμδ, αδωεεΰδ μ- 18% αωπϊ 2005.
ϊζψιν δξζεξπιν ξτςιμεϊ ωεθτϊ αψαςεο δωμιωι ωμ 2006 δρϊλν α- 793 ξμιεο $. ωεει ξζεξπιν επιιψεϊ ςψκ ρηιψιν μιεν 30 αρτθξαψ, 2006 διδ 2.1 ξμιΰψγ $.
δδεο δςφξι ωμ θας δρϊλν α- 30 αρτθξαψ, 2006, α- 10.6 ξμιΰψγ $, βιγεμ ωμ 677 ξμιεο $ μςεξϊ 30 αιεπι, 2006.
ξρτψ δξπιεϊ - πλεο μψαςεο δωμιωι ωμ 2006, ξρτψ δξπιεϊ μφεψκ ηιωεα δψεεη δπχι μξπιδ αγιμεμ ξμΰ, διπε 833.5 ξμιεο ξπιεϊ.
γιαιγπγ
γιψχθεψιεο δηαψδ, αιωιαϊε ξιεν 6 απεαξαψ, 2006, δλψιζ ςμ ϊωμεν γιαιγπγ αξζεξο αβιο δψαςεο δωμιωι ωμ ωπϊ 2006, αωιςεψ ωμ 0.34 ω"η μξπιδ (λ- 7.9 ρπθ ςμ τι ωςψ δγεμψ α- 6 απεαξαψ, 2006). διεν δχεας ιδιδ α- 14 απεαξαψ, 2006 (ιεν δΰχρ ιδιδ α- 15 απεαξαψ, 2006), ειεν δϊωμεν πχας μ- 29 απεαξαψ, 2006. ωιςεψ δξρ ωιπελδ αξχεψ ιδιδ 16%.
τψθι ωιηϊ δεςιγδ
δπδμϊ θας ϊχιιν ωιηϊ εςιγδ αιεν ωμιωι, 7 απεαξαψ, 2006, αωςδ 15:45 ωςεο ιωψΰμ (08:45 ωςεο πιε-ιεψχ) ΰωψ αδ ιιρχψε ϊεφΰεϊ δψαςεο δωμιωι ωμ 2006. πιϊο μδΰζιο μωιηδ γψκ ΰϊψ δΰιπθψπθ ωμ θας, αλϊεαϊ : www.tevapharm.com. πιϊο ιδιδ μδΰζιο μωιγεψ ηεζψ ςγ μιεν 14 απεαξαψ, 2006 αηφεϊ (ωςεο πιε-ιεψχ) αΰϊψ δηαψδ, ΰε ςμ-ιγι ηιεβ 1-877-660-6853 μξηιιβιν αϊεκ ΰψδ"α ε- 201-612-7415 μξηιιβιν ξηευ μΰψδ"α. χεγ δλπιρδ μωιγεψ δηεζψ διπε ηωαεο ξρτψ (Account #) 3055 ε- ϊε δζιδει (ID#) διπε: 217756.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ, ιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ εξεφψιν εεθψιπψιν, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. ιεϊψ ξ- 80% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |